中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2010年
21期
2901-2902
,共2页
程立新%徐玉芝%郭玉强%吕洁%李俊芳
程立新%徐玉芝%郭玉彊%呂潔%李俊芳
정립신%서옥지%곽옥강%려길%리준방
肾功能衰竭,慢性%左卡尼丁%疏血通
腎功能衰竭,慢性%左卡尼丁%疏血通
신공능쇠갈,만성%좌잡니정%소혈통
Renal failure,chronic%Levocarnitine%Shuxuetong
目的 观察左卡尼汀联合疏血通治疗慢性肾功能衰竭的临床疗效及安全性.方法 94例慢性肾功能衰竭患者按随机原则分为A组和B组各47例,A组采用左卡尼汀联合疏血通治疗,B组采用疏血通治疗.观察两组治疗总有效率、不良反应发生率及血清尿素氮、肌酐、高半胱氨酸水平.结果 两组治疗30 d后,A组治疗总有效率高于B组(P<0.05),A、B两组不良反应发生率差异无统计学意义(P>0.05).血清尿素氮、肌酐、高半胱氨酸水平治疗后A组与B组比较,差异均有统计学意义(均P<0.05).结论 在慢性肾功能衰竭患者中采用左卡尼丁联合疏血通治疗效果明显,不良反应少.
目的 觀察左卡尼汀聯閤疏血通治療慢性腎功能衰竭的臨床療效及安全性.方法 94例慢性腎功能衰竭患者按隨機原則分為A組和B組各47例,A組採用左卡尼汀聯閤疏血通治療,B組採用疏血通治療.觀察兩組治療總有效率、不良反應髮生率及血清尿素氮、肌酐、高半胱氨痠水平.結果 兩組治療30 d後,A組治療總有效率高于B組(P<0.05),A、B兩組不良反應髮生率差異無統計學意義(P>0.05).血清尿素氮、肌酐、高半胱氨痠水平治療後A組與B組比較,差異均有統計學意義(均P<0.05).結論 在慢性腎功能衰竭患者中採用左卡尼丁聯閤疏血通治療效果明顯,不良反應少.
목적 관찰좌잡니정연합소혈통치료만성신공능쇠갈적림상료효급안전성.방법 94례만성신공능쇠갈환자안수궤원칙분위A조화B조각47례,A조채용좌잡니정연합소혈통치료,B조채용소혈통치료.관찰량조치료총유효솔、불량반응발생솔급혈청뇨소담、기항、고반광안산수평.결과 량조치료30 d후,A조치료총유효솔고우B조(P<0.05),A、B량조불량반응발생솔차이무통계학의의(P>0.05).혈청뇨소담、기항、고반광안산수평치료후A조여B조비교,차이균유통계학의의(균P<0.05).결론 재만성신공능쇠갈환자중채용좌잡니정연합소혈통치료효과명현,불량반응소.
Objective To study the effects and safety of levocarnitine and shuxuetong in treatment of the patients with chronic renal failure.Methods 94 patients with chronic renal failure were selected as research object,and they were randomly divided into group A(levocarnitine and shuxuetong group) 47 cases and group B(shuxuetong group) 47 cases.Group A were treated with levocarnitine oral solution and shuxuetong,and group B were treated with shuxuetong,then the percentage of effectiveness,incidence of adverse reactions of group A and group B and serum BUN,Scr,Hcy were analyzed.Results The percentage of effectiveness of group A was higher than that of group B,but the incidence of adverse reactions of the two groups had no difference,and the serum BUN,Scr,Hcy of group A and group B before the treatment had no differences(P>0.05),those of group A and group B after treatment were compared there were significant differences(all P<0.05).Conclusion The effects of levocarnitine oral solution and shuxuetong in treatment of patients with chronic renal failure were better.